In memory of Eugenio Aringhieri, CEO Dompé, member of the EBE Board of Directors
It is with great sadness that we received the news of the sudden and untimely passing of our Board member Eugenio Aringhieri, CEO Dompé, on 1 May 2018. Eugenio Aringhieri has contributed to th...
Read moreStatement in response to the EU Council ratifying the Brexit transition deal
The associations representing the European and British life science industry (AESGP, ABPI, BIA, BGMA, EBE, EFPIA, EUCOPE, EuropaBio, Medicines for Europe, PAGB, Vaccines Europe) have today respond...
Read moreEBE at Bio Europe Spring 2018 – “Funding gaps in the European Life Science Sector”
14 March 2018 from 9h00 - 10h00 CET at RAI Amsterdam Convention Center, Room E107, Europa plein, NL 1078 GZ Amsterdam, The Netherlands The European Investment Bank (EIB) and the European Commission...
Read moreEBE Reflection Paper on Medicinal product incorporating a drug delivery device component: An Industry Perspective on the EU marketing application technical requirements, regulatory review process and post-approval device related change assessment
Within the European Biopharmaceutical Enterprises (EBE), a working group focused on EU specific topics relating to those integral combination products, which are regulated as medicinal products but wh...
Read moreEFPIA-EBE White Paper: Expedited CMC Development- Accelerated Access for Medicines of Unmet Medical Need
Since 2012 there has been a focus on faster translation of scientific breakthroughs to new, high quality medicines meeting unmet medical need through a programme initially referred to as Medicines Ada...
Read moreIncentives for Innovation. Incentivising Research in Areas of High Unmet Medical Need: Lilly’s Alzheimer’s Quest
With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcare systems....
Read morePresentations and Conference Report from the 6th EBE Annual Conference on ATMPs – 5 December 2017, London
UPDATE 12 February 2018: Conference Report now available here The remarkable opportunities that cell and gene therapies can offer, but also the seemingly increasing number of obstacles to their w...
Read moreIncentives, IP and smaller companies: the story of Lysogene
How Lysogene contributes to improving health outcomes Founded in France in 2009, and employing 18 staff at the end of 2017, Lysogene specialises in gene therapy targeting rare, neurod...
Read moreEscher Study Identifies Hurdles to ATMP Development in Europe
First results of a study into factors associated with successful development of Advanced Therapy Medicinal Products (ATMPs) were reported today by Utrecht University at European Biopharmaceuti...
Read moreIncentives for Innovation: the story of Gilenya by Novartis
With over 7,000 medicines in development, new treatments will continue to change patients’ lives, slowing disease progression, avoiding illness and reducing overall costs for healthcar...
Read more